Detalles de la búsqueda
1.
Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5â¯years of treatment.
Mol Genet Metab
; 123(4): 479-487, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29526614
2.
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays).
Bioanalysis
; 13(6): 415-463, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533276
3.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood
; 112(4): 1329-37, 2008 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17906076
4.
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay.
J Vis Exp
; (139)2018 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30247460
5.
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Clin Ther
; 39(1): 118-129.e3, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27955919
6.
Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
J Immunol Methods
; 440: 41-51, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27789297
7.
The extended auricle1 (eta1) gene is essential for the genetic network controlling postinitiation maize leaf development.
Genetics
; 165(3): 1507-19, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14668398
8.
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Clin Ther
; 37(5): 1012-1021.e6, 2015 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25487082
9.
Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
Clin Pharmacokinet
; 53(12): 1137-47, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25234648
Resultados
1 -
9
de 9
1
Próxima >
>>